Purpose: Pharmacokinetic and safety data related to the use of inhaled insulin for the management of diabetes mellitus are discussed. The various pulmonary insulin delivery systems under ...

Inhaled insulin was administered within 10 min before ... To provide at least 80% power, 143 subjects per group were required. The sample size was designed to ensure that the upper limit of ...

This is an exciting time in the treatment of diabetes. Continuous, subcutaneous insulin infusion and continuous glucose monitoring technologies are making optimal glucose control accessible to ...

Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...

An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

It took 10 years and US$1bil (RM3.77bil) for MannKind Corp to get its breakthrough inhaled-insulin drug approved by US regulators. Now comes the hard part: getting people with diabetes to use it.

Each subject received in randomized fashion a single dose of 10 International Units of insulin through subcutaneous injection (SC) in one period, and 6.5 milligrams of the inhaled insulin ...

US biotech Dance Biopharm is to work with Phillips-Medisize, to develop a version of its inhaled insulin device that has data connectivity for better management of diabetes treatment. Inhaled ...

The world's largest drug maker, Pfizer has announced that it intends to fast track its inhaled insulin Exubera in India. The world's largest drug maker, Pfizer has announced that it intends to ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship ...

“We are excited for Cipla to market the first inhaled insulin treatment option for adults living with diabetes in India and expect to prepare product for export by the end of 2025.” MannKind ...